While unable to resolve the outcome of BL-IGHV mutated patients, this study adds to the emerging evidence describing CLL with a BL-IGHV mutational status as a distinct subgroup of a heterogeneous disease, characterized by a higher frequency of specific cytogenetical abnormalities, biased IGHV gene usage, enrichment in BCR subset #2 cases, and thus very heterogeneous outcomes. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.